Prostate cancer
NEW --- Sequencing treatments in mCRPC patients without HRR gene mutations

Jens (68 years old)

Jens is a 68-year-old retired firefighter. As a volunteer, he still leads meetings to provide tips to prevent fire at home. He was earlier diagnosed with high-risk PCa (cT3N0M0; ISUP grade 4; PSA 18 ng/ml). He was treated with EBRT + 24 months ADT. His PSA nadir was 0.7 ng/ml.

2 years after completion of ADT:

  • PSA: 3.1 ng/ml
  • Testosterone: 312 ng/dl (10.8 nmol/l)
  • CT scan: enlarged pelvic lymph nodes
  • Bone scan: negative

ADT was started again. PSA nadir was 0.9 ng/ml.

18 months after start of ADT:

  • PSA: 7.6 ng/ml
  • Bone scan: 3 bone metastases; treatment with denosumab was started
  • Moderate pain; well controlled by NSAIDs
  • ALP: 132 U/l
  • Serum testosterone: 12 ng/dl (0.42 nmol/l)
  • CT scan: stable lymph nodes, no signs of visceral metastasis
  • ECOG PS: 1
  • No germline and/or somatic HRR/BRCA mutation identified

Which of the following treatment options would you choose for this patient?